Eli Lilly Responds to Patient Demands for Increased Zepbound Supply Amid Shortage
Tuesday, 2 April 2024, 14:06
Eli Lilly Responds to Zepbound Shortage
The recent shortage of Zepbound, an obesity drug produced by Eli Lilly, has raised concerns among patients. Patients are urging Eli Lilly to release more supply to meet the growing demand and ensure continued access to the medication.
Patients Advocate for Increased Supply
Amid the shortage, patient advocacy groups are calling on Eli Lilly to address the issue promptly. The availability of Zepbound is crucial for individuals managing obesity and related health conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.